Ketone Body Scaffolds and SIRT1 Activators as PPAR-δ Ligands: A Structure-Based Virtual Screening Study in the Context of Intestinal Stem Cell Biology
This structure-based virtual screening study characterizes the interaction of PPAR-δ with ketone body scaffolds and SIRT1 activators, suggesting an allosteric sensitization model for endogenous ketones, a direct ligand role for SIRT1 activators, and identifying the designed scaffold AcAc_biphenyl_001 as a promising drug-like lead for further validation in intestinal stem cell biology.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The lining of the human intestine is a bustling factory that renews itself every few days, driven by a small population of master cells at the base of tiny folds called crypts. These intestinal stem cells act as the engine of regeneration, deciding when to divide and when to rest based on the body's energy state. When a person fasts or follows a diet very low in carbohydrates, the liver produces ketone bodies, which are small molecules that serve as an alternative fuel source. For years, scientists knew that these ketone bodies helped stem cells survive and multiply, but the exact mechanism was a puzzle. One established theory suggested they worked by blocking a specific type of enzyme, but a lingering question remained: could these molecules also act as a direct key, fitting into a specific lock on the stem cells to turn on their growth machinery? This lock is a protein called PPAR-delta, a molecular switch that normally responds to fatty acids to tell cells to burn fat and grow.
A researcher named Cumhur Gokhan Ekmekci set out to solve this puzzle using a powerful computer simulation technique known as virtual screening. Instead of mixing chemicals in a test tube, the study built a digital model of the PPAR-delta protein and tested how well twenty-three different molecules fit inside its binding pocket. The library of molecules included natural ketone bodies like beta-hydroxybutyrate and acetoacetate, known activators of another protein called SIRT1, and several newly designed chemical structures based on the ketone body shape. The goal was to see if these molecules could physically dock into the protein's pocket and, if so, how tightly they held on compared to known, powerful activators.
The computer simulations revealed a clear hierarchy of how these molecules interact with the protein. As a baseline for success, the study confirmed that a known, potent drug called GW501516 fit into the protein's pocket with a very strong score, and a natural fatty acid called DHA also fit well, though less tightly. This established that the computer model was working correctly. When the natural ketone bodies were tested, they did not bind tightly enough to act as a primary switch on their own. Instead, they settled into the pocket with a weak but consistent grip across different shapes of the protein. This pattern suggests that ketone bodies might act as sensitizers, subtly lowering the barrier for the protein to be activated by other signals, rather than driving the activation directly. This finding supports a model where ketone bodies work alongside their known role in blocking enzymes, rather than replacing that role.
The study also investigated molecules known to activate SIRT1, such as resveratrol and SRT1720. The results showed that these compounds fit into the PPAR-delta pocket with surprising strength, scoring almost as well as the natural fatty acids. This suggests that these molecules might have a dual nature: they could be activating the protein directly by fitting into its pocket, in addition to their known effects on SIRT1. This is a significant possibility because it means some of the benefits seen in stem cells from these compounds might come from a direct interaction with the growth switch, not just an indirect one.
Perhaps the most exciting outcome of the study was the discovery of a newly designed molecule called AcAc_biphenyl_001. This compound was engineered to look like a ketone body but with added chemical groups to help it fit better. In the simulations, it bound to the protein with a score of minus 9.31, which is remarkably close to the powerful reference drug, yet it is less than half the size. It also passed every test for being a safe, drug-like candidate that the body could absorb. The researchers propose that this molecule could be a lead for future development, offering a way to target the intestinal stem cells more precisely than natural ketone bodies.
It is important to note that these findings come entirely from computer simulations. The study explicitly states that the method used had limitations in distinguishing true binders from non-binders in a statistical sense, meaning the absolute numbers are not a guarantee of real-world behavior. The results are best understood as a set of strong, hypothesis-generating leads that point the way forward. The researchers suggest that the next step is to test these molecules in living cell cultures to see if the computer predictions hold true. If they do, this work could open a new path for understanding how the body's metabolic state, through ketone bodies and related molecules, directly controls the renewal of the gut lining.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.